ak 2123 has been researched along with Cancer of Cervix in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chatterjee, NA; Das, K; Dobrowsky, W; Huilgol, NG; Kagiya, VT; Tatsuzaki, H | 1 |
| Dobrowsky, W; Huigol, NG; Jayatilake, RS; Kagiya, VT; Kizilbash, NI; Okkan, S; Tatsuzaki, H | 1 |
| García-Angulo, AH; Kagiya, VT | 1 |
3 trial(s) available for ak 2123 and Cancer of Cervix
| Article | Year |
|---|---|
Sanazole as a sensitizer of hypoxic cells with radical radiation in the treatment of advanced cancer of cervix an Indian experience.
Topics: Adult; Aged; Female; Humans; India; Middle Aged; Nervous System Diseases; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Rate; Triazoles; Uterine Cervical Neoplasms | 2002 |
AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomised trial.
Topics: Adult; Aged; Brachytherapy; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy; Survival Analysis; Treatment Outcome; Triazoles; Uterine Cervical Neoplasms | 2007 |
Intratumoral and parametrial infusion of a 3-nitrotriazole (AK-2123) in the radiotherapy of the uterine cervix cancer: stage II-III--preliminary positive results.
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Evaluation; Female; Humans; Radiation-Sensitizing Agents; Triazoles; Uterine Cervical Neoplasms | 1992 |